中国血液净化

›› 2006, Vol. 5 ›› Issue (2): 82-84.

• 人工肝 • 上一篇    下一篇

应用血浆灌流吸附联合血液滤过技术治疗重症肝炎的临床探讨

赵继红 王冰月 田 洁 袁 萍 杜 智   

  1. 300170 天津，天津市第三中心医院肾病中心
  • 收稿日期:1900-01-01 修回日期:1900-01-01 出版日期:2006-02-12 发布日期:2006-02-12

  • Received:1900-01-01 Revised:1900-01-01 Online:2006-02-12 Published:2006-02-12

RichHTML

0

PDF

411

摘要：

目的 探讨非生物型人工肝技术血浆灌流吸附加血液滤过疗法(PPA+HF)(Plasmaperfusion Adsorption+Hemofiltration)治疗各种原因所致重症肝炎肝衰竭的临床疗效和安全性。方法 天津市第三中心医院肾病中心15例不同病因重症肝炎患者应用PPA+HF人工肝技术进行38例次治疗，比较治疗前后患者生化指标肝功能、凝血酶原时间、血氨及临床症状改善程度及观察治疗不良反应对临床疗效和安全性评价。结果 患者在治疗后意识障碍、黄疸、乏力﹑恶心﹑呕吐﹑腹胀、纳差等症状明显改善,食欲增加，血清总胆红素﹑直接胆红素﹑血氨分别较前下降了32.4%、46.1%、63.8%。血浆白蛋白﹑转氨酶﹑肾功能较前好转,凝血酶原时间由治疗前(20.61±12.26)%上升为 (31.18±9.06)%上升了47.65%, 出血倾向得到纠正。血白细胞、血小板及电解质水平无明显变化。未发生出血、休克、过敏等并发症，患者耐受好。 结论 (PPA+HF)人工肝技术可显著改善各种原因引起的重症肝炎肝衰竭患者临床症状及生化指标，安全性好，无明显不良反应,近期疗效显著。可作为支持治疗、外科手术和肝移植的术前过渡治疗手段。

关键词: 血浆灌流吸附, 血液滤过, 重症肝炎, 肝衰竭

Abstract: Objective To evaluate clinical significance,feasibility and security of the PP and HF in treating severe hepatitis patients with liver failure. Methods Thirty-eight treatments of PP and HF were taken in 15 patients with severe hepatitis. The change of clinical symptoms, liver function, plasma thrombinogen time(PT) and ammonia were observed to determine the clinical effects. The feasibility and security were determined by therapy related adverse reactions and tolerance of the patients. Results After the treatment, the clinical symptoms such as conscious disturbance, jaundice, intertia, abdominal distention were better than before. The serum bilirubin decreased and PT increased significantly (P＜0.05). No severe hemorrhage, shock or other adverse reactions occurred. All patients could tolerate the therapy. Conclusion The therapy is safe and can significantly improve the symptoms, blood parameters and short-term mortality in patients with severe hepatitis.

Key words: Hemofiltration, Severe hepatitis, Liver failure

中图分类号: